P1‐078: Reduced Thiamine Diphosphate Level Contributes to Brain Glucose Hypometabolism and Neurodegeneration in Alzheimer's Disease

Shaoming Sang,Huimin Liu,Xiaoli Pan,Shumei Pan,Yun Wang,Xiang Yu,Chunjiu Zhong

DOI: https://doi.org/10.1016/j.jalz.2015.06.275

2015-01-01

Abstract:The pathogenesis of Alzheimer's disease (AD) remains elusive. Brain glucose hypometabolism, an invariant feature, precedes and closely correlates with clinical symptoms and signs in AD. To clarify the mechanism of cerebral glucose metabolism will help to understand AD pathogenesis. Cerebral glucose metabolism was evaluated by FDG-PET in AD patients and the mice with thiamine deficiency (TD) by diet deprivation. Brain amyloid deposit was measured by PiB-PET. Thiamine diphosphate (TDP), thiamine monophosphate, and thiamine levels were detected by high performance liquid chromatography. The diagnostic value of blood TDP level for AD was analyzed. The effects of thiamine metabolism on dendrtic branching, spine, and soma size of enurons were investigated by inhibiting thiamine pyrophosphokinase (TPK), the key enzyme of thiamine metabolism, and transporters (SLC19A2, SLC19A3, SLC25A19) via TPK antagonist (pyrithiamine) and/or RNA interference. Blood TDP level in AD patients and blood and brain TDP levels in TD mice were significantly reduced as compared with that in control groups (n=1199 for human subjects and n=6 for mice), patients with vascular dementia (n=67) and frontotemporal dementia (n=13, all P<0.001). Blood TDP level in AD patients (n=14) and blood/brain TDP levels in TD mice (n=6) was closely correlated with glucose metabolism of cotices examined. Blood TDP level exhibited a promising value for AD diagnosis (0.830 of AUC, 76.5% of sensititvity, and 77.5% of specificity) and differential diagnosis from vascular dementia and frontotemporal dementia. Brain amyloid deposit in AD patients was not significantly correlated with blood TDP level (n=32). Pyrithiamine and RNA interference against TPK and transporters (SLC19A2, SLC19A3, SLC25A19) significantly reduced dendritic brainching, spine density, and soma size of neurons (n=9-64 in 3 batches of cultured hippocampal neurons). The disruption of thiamie metabolism in AD contributes to brain glucose hypometabolism and neurodegeneration. Combinging with the previous studies, we propose that AD is a metabolic disorder and hypothesize that disrutped thiamiine metabolism directly contributes to AD pathogenesis by perturbing glucose utilization and inducing multiple pathogenic factors in the brain. Altered thiamine metabolism is a useful diagnostic biomarker for AD and a potential target for the disease-modifying study.